| Psychometric validation of the Persian version of the CarerQol-7D instrument on caregivers of patients with multiple sclerosis H Faraji, I Akbarzadeh, M Yaseri, MA Sahraian, S Nikfar Current Journal of Neurology, 59-65, 2024 | | 2024 |
| Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what’s new? S Mozaffari, S Nikfar, M Abdollahi Expert Opinion on Drug Metabolism & Toxicology 20 (5), 307-317, 2024 | | 2024 |
| Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs S Mozaffari, S Nikfar, M Abdollahi Expert Opinion on Investigational Drugs, 2024 | 1 | 2024 |
| Advancements in pharmacotherapy options for treating diabetes in children and adolescents M Daniali, S Nikfar, M Abdollahi Expert Review of Endocrinology & Metabolism 19 (1), 37-47, 2024 | | 2024 |
| Systematic Review of Patient Preference Studies in Non-metastatic Breast Cancer Adjuvant Medication Therapy: Attribute Selection A Homayouni, S Nikfar, FM Rajabi, M Nili, KM Kelly, A Abdollahiasl IJ Pharmaceutical Research 23 (1), 2024 | | 2024 |
| Cost-Effectiveness Analysis of Pharmacogenomics-Guided Versus Standard Dosing of Warfarin in Patients with Mechanical Prosthetic Heart Valve H Hemati, M Nosrati, M Hasanzad, P Rahmani, S Fariman, M Sarabi, ... IJ Pharmaceutical Research 23 (1), 2024 | | 2024 |
| Choosing the Best Instrument for Measuring Health Spillover Effect in Caregivers of Patients With Multiple Sclerosis H Faraji, F Soleymani, M Yaseri, MA Sahraian, A Abdollahiasl, A Meftah, ... Value in Health Regional Issues 39, 49-56, 2024 | | 2024 |
| Pharmacotherapy for gastric and intestinal cramping pain: current and emerging therapies T Mousavi, M Sharifnia, S Nikfar, M Abdollahi Expert Opinion on Pharmacotherapy 24 (18), 2021-2033, 2023 | | 2023 |
| Is There Any Benefit in Extended-Interval Dosing Regimen of Natalizumab for Patients with Relapsing-Remitting Multiple Sclerosis? Results from a Systematic Review and Meta-Analysis T Mousavi, B Fatemi, S Nikfar, MA Sahraian Multiple Sclerosis and Related Disorders 80, 105334, 2023 | | 2023 |
| A cost-effectiveness analysis of linagliptin add-on to insulin treatment for patients with type 2 diabetes mellitus and chronic kidney disease in Iran SA Fariman, M Nosrati, P Rahmani, S Nikfar Journal of Diabetes & Metabolic Disorders 22 (2), 1263-1271, 2023 | 1 | 2023 |
| Towards greater impact in health technology assessment: System dynamic approach for new and emerging technologies in Iran Z Goudarzi, MA Marzaleh, S Nikfar, A Kebriaeezadeh, RY Zenouz, ... DARU Journal of Pharmaceutical Sciences, 1-21, 2023 | | 2023 |
| Common gastrointestinal drug-drug interactions in geriatrics and the importance of careful planning S Mozaffari, T Mousavi, S Nikfar, M Abdollahi Expert Opinion on Drug Metabolism & Toxicology 19 (11), 807-828, 2023 | 3 | 2023 |
| Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran A Tajik, S Nikfar, S Elyasi, O Rajabi, M Varmaghani Child and Adolescent Psychiatry and Mental Health 17 (1), 115, 2023 | 1 | 2023 |
| Upfront DPYD genotype-guided treatment for fluoropyrimidine-based chemotherapy in advanced and metastatic colorectal cancer: a cost-effectiveness analysis SA Fariman, ZJ Rafsanjani, M Hasanzad, K Niksalehi, S Nikfar Value in Health Regional Issues 37, 71-80, 2023 | 4 | 2023 |
| An updated systematic review and dose-response meta-analysis on the relation between exposure to arsenic and risk of type 2 diabetes NR Kakavandi, T Mousavi, T Asadi, A Moradi, M Esmaeili, AH Sezavar, ... Toxicology letters, 2023 | 6 | 2023 |
| How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment S Zartab, S Nikfar, A Jamshidi, M Toroski, V Varahrami, B Fatemi, ... Expert Review of Pharmacoeconomics & Outcomes Research 23 (6), 701-708, 2023 | | 2023 |
| Pharmacoeconomic evaluation of insulin aspart and glargine in type 1 and 2 diabetes mellitus in Iran M Nosrati, S Ahmadi Fariman, P Saiyarsarai, S Nikfar Journal of Diabetes & Metabolic Disorders 22 (1), 817-825, 2023 | | 2023 |
| Cost-effectiveness comparison between ticagrelor and clopidogrel in acute coronary syndrome in Iran A Hashemi-Meshkini, A Tajik, N Ayati, S Nikfar, R Koochak, ... The Journal of Tehran University Heart Center 18 (2), 94, 2023 | 4 | 2023 |
| An update on the use of pharmacotherapy for opioid-induced bowel dysfunction T Mousavi, S Nikfar, M Abdollahi Expert Opinion on Pharmacotherapy 24 (3), 359-375, 2023 | 1 | 2023 |
| A Systematic Review and Meta-analysis on Safety and Effectiveness of Extended-interval Dosing of Natalizumab in Patients with Relapsing-remitting Multiple Sclerosis: Is There … T Mousavi, B Fatemi, S Nikfar, MA Sahraian Neurology Letters 2 (Supplementary 1 (20th Iranian Multiple Sclerosis Congress)), 2023 | | 2023 |
Prof Dr Mohammad AbdollahiFaculty of Pharmacy & Pharmaceutical Sciences Research Center (PSRC)(TUMS)在 TUMS.Ac.Ir 的电子邮件经过验证
